uniQure N.V. Company Profile (NASDAQ:QURE)

About uniQure N.V. (NASDAQ:QURE)

uniQure N.V. logoUniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company's product candidates within the Core Program include AMT-060 for Hemophilia B, AMT-130 for Huntington's disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:QURE
  • CUSIP: N/A
  • Web: www.uniqure.com
Capitalization:
  • Market Cap: $196.81 million
  • Outstanding Shares: 25,560,000
Average Prices:
  • 50 Day Moving Avg: $7.77
  • 200 Day Moving Avg: $6.23
  • 52 Week Range: $4.72 - $9.15
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.92
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $24.62 million
  • Price / Sales: 7.99
  • Book Value: $1.07 per share
  • Price / Book: 7.20
Profitability:
  • EBIDTA: ($59,260,000.00)
  • Net Margins: -203.99%
  • Return on Equity: -135.97%
  • Return on Assets: -40.45%
Debt:
  • Debt-to-Equity Ratio: 0.59%
  • Current Ratio: 4.82%
  • Quick Ratio: 4.82%
Misc:
  • Average Volume: 140,502 shs.
  • Beta: 0.42
  • Short Ratio: 5.43
 

Frequently Asked Questions for uniQure N.V. (NASDAQ:QURE)

What is uniQure N.V.'s stock symbol?

uniQure N.V. trades on the NASDAQ under the ticker symbol "QURE."

How were uniQure N.V.'s earnings last quarter?

uniQure N.V. (NASDAQ:QURE) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.05. The company had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.92 million. uniQure N.V. had a negative net margin of 203.99% and a negative return on equity of 135.97%. View uniQure N.V.'s Earnings History.

When will uniQure N.V. make its next earnings announcement?

uniQure N.V. is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for uniQure N.V..

Where is uniQure N.V.'s stock going? Where will uniQure N.V.'s stock price be in 2017?

7 brokers have issued twelve-month target prices for uniQure N.V.'s shares. Their forecasts range from $8.00 to $27.00. On average, they expect uniQure N.V.'s share price to reach $16.00 in the next twelve months. View Analyst Ratings for uniQure N.V..

What are analysts saying about uniQure N.V. stock?

Here are some recent quotes from research analysts about uniQure N.V. stock:

  • 1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (8/24/2017)
  • 2. Cowen and Company analysts commented, "QURE reported 1Q17 financials and presented multiple updates at ASGCT recently." (5/24/2017)

Who are some of uniQure N.V.'s key competitors?

Who owns uniQure N.V. stock?

uniQure N.V.'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (6.13%), Spark Investment Management LLC (1.02%), Tekla Capital Management LLC (0.95%), DAFNA Capital Management LLC (0.80%), P.A.W. Capital Corp (0.49%) and Macquarie Group Ltd. (0.28%). View Institutional Ownership Trends for uniQure N.V..

Who sold uniQure N.V. stock? Who is selling uniQure N.V. stock?

uniQure N.V.'s stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC and P.A.W. Capital Corp. View Insider Buying and Selling for uniQure N.V..

Who bought uniQure N.V. stock? Who is buying uniQure N.V. stock?

uniQure N.V.'s stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Mangrove Partners and JPMorgan Chase & Co.. View Insider Buying and Selling for uniQure N.V..

How do I buy uniQure N.V. stock?

Shares of uniQure N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is uniQure N.V.'s stock price today?

One share of uniQure N.V. stock can currently be purchased for approximately $7.70.


MarketBeat Community Rating for uniQure N.V. (NASDAQ QURE)
Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  407
MarketBeat's community ratings are surveys of what our community members think about uniQure N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for uniQure N.V. (NASDAQ:QURE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $16.00 (107.79% upside)

Analysts' Ratings History for uniQure N.V. (NASDAQ:QURE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/23/2017Chardan CapitalSet Price TargetBuy$13.00HighView Rating Details
6/30/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$17.00LowView Rating Details
5/24/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingHold$8.00LowView Rating Details
12/2/2016Leerink SwannReiterated RatingOutperformN/AView Rating Details
12/6/2016WallachBeth CapitalLower Price TargetBuy$27.00 -> $15.00N/AView Rating Details
11/15/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
8/4/2016HC WainwrightInitiated CoverageBuy$21.00N/AView Rating Details
1/8/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
1/8/2016Roth CapitalReiterated RatingBuy$37.00N/AView Rating Details
(Data available from 8/24/2015 forward)

Earnings

Earnings History for uniQure N.V. (NASDAQ:QURE)
Earnings by Quarter for uniQure N.V. (NASDAQ:QURE)
Earnings History by Quarter for uniQure N.V. (NASDAQ QURE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/28/2017        
8/8/20176/30/2017($0.78)($0.83)$2.92 million$4.94 millionViewN/AView Earnings Details
5/9/20173/31/2017($0.64)($0.80)$4.20 million$3.32 millionViewN/AView Earnings Details
5/31/2016Q1($0.82)($0.93)$2.94 million$4.30 millionViewN/AView Earnings Details
4/4/2016Q415($0.60)($0.58)$2.78 million$6.78 millionViewN/AView Earnings Details
11/30/2015Q315($0.64)($1.14)$7.76 million$3.50 millionViewListenView Earnings Details
8/27/2015Q215($0.56)($0.98)$31.18 million$1.79 millionViewN/AView Earnings Details
6/11/2015Q1($0.82)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details
4/6/2015($0.62)($0.77)$1.38 million$1.61 millionViewN/AView Earnings Details
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details
9/2/2014Q214($0.55)($1.35)$1.40 million$1.37 millionViewN/AView Earnings Details
6/6/2014($0.45)($0.52)$0.84 million$1.59 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for uniQure N.V. (NASDAQ:QURE)
2017 EPS Consensus Estimate: ($3.04)
2018 EPS Consensus Estimate: ($2.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.71)($0.71)($0.71)
Q2 20172($0.81)($0.71)($0.76)
Q3 20172($0.85)($0.84)($0.85)
Q4 20172($0.86)($0.58)($0.72)
Q1 20181($0.81)($0.81)($0.81)
Q2 20181($0.80)($0.80)($0.80)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for uniQure N.V. (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for uniQure N.V. (NASDAQ:QURE)
Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 29.00%
Insider Trades by Quarter for uniQure N.V. (NASDAQ:QURE)
Institutional Ownership by Quarter for uniQure N.V. (NASDAQ:QURE)
Insider Trades by Quarter for uniQure N.V. (NASDAQ:QURE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/29/2017Harald PetryInsiderSell49,300$6.02$296,786.00View SEC Filing  
6/27/2017Harald PetryInsiderSell65,930$6.01$396,239.30View SEC Filing  
6/26/2017Harald PetryInsiderSell58,075$6.01$349,030.75View SEC Filing  
6/22/2017Harald PetryInsiderSell155$6.00$930.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for uniQure N.V. (NASDAQ:QURE)
Latest Headlines for uniQure N.V. (NASDAQ:QURE)
Source:
DateHeadline
americanbankingnews.com logoQ3 2017 Earnings Estimate for uniQure N.V. Issued By Oppenheimer Holdings (QURE)
www.americanbankingnews.com - August 23 at 8:10 AM
seekingalpha.com logouniQure: A Busted Biotech IPO Worth Owning - Seeking Alpha
seekingalpha.com - August 22 at 6:09 AM
americanbankingnews.com logouniQure N.V. (QURE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 19 at 4:48 PM
americanbankingnews.com logoQ3 2017 Earnings Forecast for uniQure N.V. (NASDAQ:QURE) Issued By Leerink Swann
www.americanbankingnews.com - August 11 at 8:12 AM
americanbankingnews.com logoAnalysts Set Expectations for uniQure N.V.'s FY2019 Earnings (NASDAQ:QURE)
www.americanbankingnews.com - August 10 at 1:32 PM
nasdaq.com logouniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress - Nasdaq
www.nasdaq.com - August 10 at 7:13 AM
americanbankingnews.com logouniQure N.V. (QURE) Announces Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - August 9 at 4:46 PM
globenewswire.com logouniQure Announces Second Quarter 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:45 AM
finance.yahoo.com logouniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress
finance.yahoo.com - August 9 at 6:45 AM
finance.yahoo.com logoUniQure reports 2Q loss
finance.yahoo.com - August 9 at 6:45 AM
globenewswire.com logouniQure Announces Leadership Team Appointments and ... - GlobeNewswire (press release)
globenewswire.com - August 8 at 6:32 AM
americanbankingnews.com logouniQure N.V. (NASDAQ:QURE) Expected to Post Quarterly Sales of $2.92 Million
www.americanbankingnews.com - August 7 at 9:06 AM
americanbankingnews.com logo Analysts Anticipate uniQure N.V. (NASDAQ:QURE) Will Post Earnings of -$0.86 Per Share
www.americanbankingnews.com - August 5 at 7:08 AM
reuters.com logoBRIEF-Uniqure reacquires development and commercialization rights for gene therapy candidate in Hemophilia B - Reuters
www.reuters.com - August 2 at 6:57 AM
globenewswire.com logouniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B - GlobeNewswire (press release)
globenewswire.com - August 2 at 6:57 AM
americanbankingnews.com logouniQure N.V. (NASDAQ:QURE) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - August 2 at 12:22 AM
streetinsider.com logouniQure (QURE) Reacquires Rights for its Gene Therapy Candidate in Hemophilia B
www.streetinsider.com - August 1 at 5:13 AM
feeds.benzinga.com logouniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B
feeds.benzinga.com - July 31 at 7:34 AM
americanbankingnews.com logouniQure N.V. (QURE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 25 at 4:51 PM
americanbankingnews.com logoChardan Capital Analysts Give uniQure N.V. (NASDAQ:QURE) a $13.00 Price Target
www.americanbankingnews.com - July 24 at 2:52 PM
globenewswire.com logouniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene ... - GlobeNewswire (press release)
globenewswire.com - July 22 at 8:03 AM
nasdaq.com logouniQure NV (QURE) Shows Strength: Stock Moves 9.1% Higher - Nasdaq
www.nasdaq.com - July 22 at 8:03 AM
finance.yahoo.com logouniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program
finance.yahoo.com - July 22 at 8:03 AM
globenewswire.com logouniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell ... - GlobeNewswire (press release)
globenewswire.com - July 19 at 6:25 AM
finance.yahoo.com logouniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing
finance.yahoo.com - July 18 at 7:45 AM
americanbankingnews.com logo$2.92 Million in Sales Expected for uniQure N.V. (QURE) This Quarter
www.americanbankingnews.com - July 15 at 7:34 AM
americanbankingnews.com logo-$0.86 EPS Expected for uniQure N.V. (QURE) This Quarter
www.americanbankingnews.com - July 13 at 10:18 PM
streetinsider.com logouniQure (QURE) Reports Updated Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
www.streetinsider.com - July 11 at 6:57 AM
finance.yahoo.com logouniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
finance.yahoo.com - July 11 at 6:57 AM
finance.yahoo.com logouniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies
finance.yahoo.com - July 11 at 6:57 AM
americanbankingnews.com logouniQure N.V. (QURE) Given "Outperform" Rating at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 30 at 7:46 PM
americanbankingnews.com logouniQure N.V. (QURE) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 30 at 12:44 PM
americanbankingnews.com logoHarald Petry Sells 49,300 Shares of uniQure N.V. (QURE) Stock
www.americanbankingnews.com - June 29 at 7:47 PM
americanbankingnews.com logoHarald Petry Sells 58,075 Shares of uniQure N.V. (QURE) Stock
www.americanbankingnews.com - June 28 at 10:23 PM
americanbankingnews.com logouniQure N.V. (QURE) Insider Harald Petry Sells 65,930 Shares
www.americanbankingnews.com - June 28 at 7:24 PM
streetinsider.com logouniQure (QURE) Reports Presentations at ISTH
www.streetinsider.com - June 23 at 8:16 PM
globenewswire.com logouniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis ... - GlobeNewswire (press release)
globenewswire.com - June 23 at 9:24 AM
americanbankingnews.com logoComparing uniQure N.V. (QURE) & BIOVERATIV INC (BIVV)
www.americanbankingnews.com - June 20 at 12:30 PM
americanbankingnews.com logoZacks: Brokerages Anticipate uniQure N.V. (QURE) Will Announce Earnings of -$0.86 Per Share
www.americanbankingnews.com - June 19 at 10:26 PM
nasdaq.com logouniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based ... - Nasdaq
www.nasdaq.com - June 16 at 8:29 PM
streetinsider.com logoForm 8-K uniQure NV For: Jun 14 - StreetInsider.com
www.streetinsider.com - June 16 at 3:27 PM
finance.yahoo.com logouniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies
finance.yahoo.com - June 15 at 4:19 PM
seekingalpha.com logoUniqure N.V. (QURE) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 13 at 10:11 AM
globenewswire.com logouniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - June 6 at 8:32 PM
finance.yahoo.com logouniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer
finance.yahoo.com - June 6 at 8:32 PM
americanbankingnews.com logoUniqure NV (QURE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 5 at 11:11 AM
americanbankingnews.com logoUniqure NV (QURE) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 3 at 2:02 PM
finance.yahoo.com logouniQure NV :QURE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 10:22 PM
nasdaq.com logouniQure Announces Company Presentation at Jefferies Healthcare ... - Nasdaq
www.nasdaq.com - June 1 at 8:57 PM
globenewswire.com logouniQure Announces Company Presentation at Jefferies Healthcare ... - GlobeNewswire (press release)
globenewswire.com - June 1 at 8:34 AM

Social

Chart

uniQure N.V. (QURE) Chart for Thursday, August, 24, 2017

This page was last updated on 8/24/2017 by MarketBeat.com Staff